Recruiting
Plasma cell myeloma refractory
RecruitingA study of the safety and effectiveness of REGN17372 and linvoseltamab in adults with relapsed or refractory multiple myeloma
Registered drugNo placebo
A study of the safety and effectiveness of REGN17372 and linvoseltamab in adults with relapsed or refractory multiple myeloma
Registered drugNo placebo
- Disease:Plasma cell myeloma refractory
- Substances:DexamethasoneLinvoseltamab+3
Countries:
Greece
Greece- Participants:18–64 years · 65+ years
- Substances:Dexamethasone
